atezolizumab breast cancer

Release time ：Dec-28,2024

Atezolizumab is an immunotherapy medication indicated for the treatment of certain breast cancer types. It functions by inhibiting the interaction between PD-L1 protein and PD-1 receptor, thereby stimulating T cells to combat cancer cells. This drug is typically administered in conjunction with other medications to optimize treatment outcomes.

Adverse effects may arise during atezolizumab therapy for breast cancer, such as fatigue, nausea, vomiting, diarrhea, and rash. While these side effects are generally mild, they can occasionally be severe or even life-threatening. Consequently, it is essential for patients undergoing atezolizumab treatment to have regular blood tests and other assessments to monitor their body's response to the medication and the emergence of any side effects.

Patients receiving atezolizumab should adhere to their physician's recommendations and not alter the dosage or discontinue the medication without guidance. Additionally, maintaining healthy lifestyle practices, including a balanced diet, regular exercise, and adequate sleep, can assist the body in managing the stress and side effects associated with treatment. In the event of severe side effects or a deterioration in condition, immediate medical attention is advised, and it is crucial to inform the healthcare provider about the ongoing atezolizumab therapy.